Posted by Michael Wonder on 26 Nov 2020
Bio-Thera Solutions submits marketing authorisation application for BAT1706, a proposed biosimilar to Avastin, to European Medicines Agency
25 November 2020 - Bio-Thera Solutions today announced that it has submitted the marketing authorisation application for BAT1706, a proposed biosimilar to Avastin (bevacizumab), to EMA.
Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the European Union Member States, Iceland, Norway and Liechtenstein.
